FDA Approves Yeztugo: A Game-Changing Twice-Yearly Injection For HIV Prevention
New Delhi: On June 18, 2025, Gilead Sciences’ lenacapavir, marketed as Yeztugo, received FDA approval as the first HIV pre-exposure prophylaxis (PrEP) agent that was shown to almost perfectly prevent HIV infections when injected twice…